SynBioBeta Speaker
Wenning Qin
Senior Vice President, Innovation and Process Development
eGenesis
YEAR
25
May 2025, SynBioBeta
Keynote Speaker
Dr. Wenning Qin is Senior Vice President, Innovation and Process Development, at eGenesis. She earned a B. S. in Public Health from Tongji Medical University (Wuhan, China), an M. S. in cardiovascular physiology from the same institution, and a Ph. D. in cardiovascular pharmacology from Southern Illinois University (Carbondale, IL.). Her postdoctoral training was in transcriptional regulation of gene expression from Washington University School of Medicine (St. Louis, MO). She has over 25 years of experience in genome engineering and leadership in delivering results. Her previous professional associations included Monsanto Life Sciences, Pharmacia Corporation, Pfizer Inc., Biogen Idec, and the Jackson Laboratory. In her role with eGenesis, she is responsible for porcine genome engineering and innovation strategies and executions, aspiring to bringing porcine cells, tissues, and organs to clinical practice and transforming the treatment of organ failure.
SynBioBeta 2025 - Keynote
Synthetic Biology Frontiers in Transplantation: Engineering Durable Therapeutic Solutions
This cutting-edge session explores the intersection of synthetic biology, materials science, and transplantation medicine to address key challenges in cell, tissue, and organ transplantation. We'll examine innovative approaches to enhance transplant durability, improve integration with host systems, and advance the field of regenerative medicine. Examples include: genetically engineered cells for enhanced survival, 3d-printed scaffolds and organoids, advances in xenotransplantation, and others.
All Categories